Labcorp announces retirement of EVP and COO Mark Schroeder

Q: What executive leadership change did Labcorp (LH) disclose?

Labcorp disclosed that Mark Schroeder, its Executive Vice President, President, Diagnostics Laboratories and Chief Operations Officer, has informed the company of his intention to retire.

Q: What roles does Mark Schroeder currently hold at Labcorp (LH)?

Mark Schroeder serves as Executive Vice President, President, Diagnostics Laboratories and Chief Operations Officer of Labcorp Holdings Inc.

Labcorp Holdings Inc. reports that Mark Schroeder, its Executive Vice President, President, Diagnostics Laboratories and Chief Operations Officer, has notified the company of his intention to retire.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

Labcorp Holdings Inc. reports that Mark Schroeder, its Executive Vice President, President, Diagnostics Laboratories and Chief Operations Officer, has notified the company of his intention to retire.

His retirement is expected to be effective on April 1, 2026, giving the company time to manage the transition of responsibilities across its diagnostics laboratories operations and broader executive team.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What executive leadership change did Labcorp (LH) disclose?

Labcorp disclosed that Mark Schroeder, its Executive Vice President, President, Diagnostics Laboratories and Chief Operations Officer, has informed the company of his intention to retire.

When will Mark Schroeder retire from Labcorp (LH)?

The company states that Mark Schroeder’s retirement is expected to be effective on April 1, 2026.

What roles does Mark Schroeder currently hold at Labcorp (LH)?

Mark Schroeder serves as Executive Vice President, President, Diagnostics Laboratories and Chief Operations Officer of Labcorp Holdings Inc.

On what date did Labcorp receive Mark Schroeder’s retirement notice?

Labcorp received Mark Schroeder’s notice of his intention to retire on December 9, 2025.

Does Labcorp’s update mention who will replace Mark Schroeder?

The update only states that Mark Schroeder intends to retire effective April 1, 2026; it does not identify a successor in this disclosure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 12/15/2025 - 04:03 PM EST

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

December 9, 2025

(Date of earliest event reported)

LABCORP HOLDINGS INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware

1-11353

99-2588107

(State or other jurisdiction of Incorporation)

(Commission File Number)

(I.R.S. Employer Identification No.)

358 South Main Street

Burlington

North Carolina

27215

(Address of principal executive offices)

(Zip Code)

(Registrant’s telephone number including area code) 336-229-1127

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


☐			Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Exchange Act:

Title of each class

Trading Symbol

Name of exchange on which registered

Common Stock, $0.10 par value

New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

☐


Item 5.02			Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On December 9, 2025, Mark Schroeder, the Executive Vice President and President, Diagnostics Laboratories and Chief Operations Officer of Labcorp Holdings Inc. (the “Company”), notified the Company of his intention to retire, effective on April 1, 2026.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

LABCORP HOLDINGS INC.

Registrant



Date: December 15, 2025	By:	/s/ SANDRA D. VAN DER VAART
		Sandra D. van der Vaart
		Executive Vice President, Chief Legal Officer and Corporate Secretary

Source: View Original Filing on SEC EDGAR